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Abstract 
Mitochondrial dysfunction is associated with various forms of lung 
injury and disease that also involve alterations in pulmonary endothelial 
permeability, but the relationship, if any, between the two is not well 
understood. This question was addressed by perfusing the isolated intact rat 
lung with a buffered physiological saline solution in the absence or presence 
of the mitochondrial complex I inhibitor rotenone (20 uM). As compared to 
control, rotenone depressed whole lung tissue ATP from 5.66 ± 0.46 (SEM) to 
2.34 ± 0.15 (SEM) μmol·gram−1 dry lung, with concomitant increases in the 
ADP:ATP and AMP:ATP ratios. Rotenone also increased lung perfusate lactate 
(from 12.36 ± 1.64 (SEM) to 38.62 ± 3.14 μmol·15 min−1 perfusion·gm−1 dry 
lung) and the lactate:pyruvate ratio, but had no detectable impact on lung 
tissue GSH:GSSG redox status. The amphipathic quinone, coenzyme Q1 
(CoQ1; 50 μM) mitigated the impact of rotenone on the adenine nucleotide 
balance, wherein mitigation was blocked by NAD(P)H:quinone oxidoreductase 
1 (NQO1) or mitochondrial complex III inhibitors. In separate studies, 
rotenone increased the pulmonary vascular endothelial filtration coefficient 
(Kf) from 0.043 ± 0.010 (SEM) to 0.156 ± 0.037 (SEM) ml·min−1·cm 
H2O−1·gm−1 dry lung weight, and CoQ1 protected against the effect of 
rotenone on Kf. A second complex I inhibitor, piericidin A, qualitatively 
reproduced the impact of rotenone on Kf and the lactate/pyruvate ratio. 
Taken together, the observations imply that pulmonary endothelial barrier 
integrity depends on mitochondrial bioenergetics as reflected in lung tissue 
ATP levels and that compensatory activation of whole lung glycolysis cannot 
protect against pulmonary endothelial hyperpermeability in response to 
mitochondrial blockade. The study further suggests that low molecular weight 
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amphipathic quinones may have therapeutic utility in protecting lung barrier 
function in mitochondrial insufficiency. 
Keywords: Pulmonary endothelial permeability, pulmonary endothelium, 
quinone, mitochondrial electron transport complex I, perfused lung, 
pulmonary endothelial filtration coefficient (Kf) 
Introduction 
Studies in the isolated perfused lung have revealed that ~80 – 
85% of total lung ATP is derived from mitochondrial respiration [1]. 
Pro-oxidant and other pathophysiological stresses target components 
of lung mitochondria, including mitochondrial DNA (mtDNA) itself, 
mitochondrial complex I and other complexes, and the tricarboxylic 
acid cycle enzyme aconitase [2-6]. Mitochondrial bioenergetic 
dysfunction arising from these and other lesions has been implicated in 
various forms of clinical and experimental lung injury [7-16]. While 
mitochondrial dysfunction is an all-purpose term for a panoply of 
possible adverse effects on mitochondrial respiration and other 
mitochondrial functions, a key readout, that may also underlie certain 
manifestations of lung injury, is impairment of ATP generating capacity 
[9, 16-21]. 
Acute lung injury is characterized by increased permeability of 
the pulmonary endothelial barrier followed by accumulation of protein-
enriched fluid in the airspaces and interstitium and impairment of gas 
exchange [22]. Yet studies manipulating lung mitochondrial 
bioenergetics as a means to discern its contribution to pulmonary 
endothelial function have focused primarily on metabolic rather than 
barrier function, with pulmonary edema used mostly as a toxicity 
endpoint [23, 24]. The latter studies also involved nearly complete 
dissipation of mitochondrial ATP generation, e.g., blockade of the 
terminal chain component, cytochrome oxidase, or use of 
mitochondrial electron transport uncouplers, and thus did not address 
a perhaps more likely pathophysiological scenario involving partial 
impairment at upstream mitochondrial targets. For example, 
mitochondrial complex I activity is depressed by ~60% in lungs of rats 
breathing elevated O2 (85% O2 for 48 hrs) compared to those in room 
air, with no detectable effects on complexes III or IV [2]. While the 
functional impact of the effect on complex I activity was not 
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specifically investigated, there was no discernible pulmonary edema 
resulting from the hyperoxic exposure, as reflected in lung wet-to-dry 
weight ratios [2]. On the other hand, in rabbits exposed to 100% O2 
for 48 hours, while there was also little change in lung water or arterial 
blood gases in the intact animal, the pulmonary endothelial filtration 
coefficient (Kf) increased, portending compromised endothelial barrier 
integrity [25]. Thus, we asked whether there could be a link between 
mitochondrial complex I activity blockade, mitochondrial function 
reflected as diminished ATP generation and pulmonary endothelial 
barrier function. 
To address this question, acute exposure to the classical 
complex I inhibitor, rotenone, was used to induce complex I blockade 
in the perfused rat lung [26]. Rotenone was selected because our 
previous studies in this preparation revealed that it caused nearly 
complete blockade of complex I and depression of whole lung oxygen 
consumption with no detectable impact on complexes III and IV [2, 
27]. To determine the impact of rotenone on lung ATP levels and 
energy charge, lung tissue adenine nucleotides (ATP, ADP and AMP) 
were measured. Measurements of lung lactate and pyruvate efflux 
were also included to evaluate glycolytic activity and lung tissue 
cytosolic redox status. Finally, the rotenone effect on lung vascular 
endothelial permeability was measured as the pulmonary endothelial 
filtration coefficient (Kf) [22]. 
Complex I inhibition has the advantage in that it provides a 
convenient model of the mitochondrial response in the hyperoxia-
exposed rat lung, wherein downstream electron transport complexes 
remain open as electron acceptors [2]. This allows for the possibility of 
restoration of mitochondrial electron transport given the appropriate 
electron donor or substrate. One possible donor is exemplified by low 
molecular weight amphipathic hydroquinones that shuttle reducing 
equivalents from cytosolic NAD(P)H to complex III, effecting a so-
called bypass of a complex I block (Scheme 1) [28-30]. This is 
proposed as a mechanism underlying the therapeutic effect of 
quinones in treatment of neurological and other diseases arising from 
mitochondrial genetic disorders, in experimental complex I dysfunction 
or coenzyme Q10 deficiencies in other organs and cell types [28-32]. 
However, quinones as substrates for reactivation of mitochondrial 
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electron transport and restoration of mitochondria-dependent lung 
function have not been considered. 
 
Scheme 1 Quinone-mediated mitochondrial electron transport complex I 
bypass 
A. The mitochondrial electron transport chain under physiological conditions, where 
C(I), C(III), C(IV) and C(V) represent complexes I, III, IV and V, and with the 
physiological quinone electron acceptor, CoQ10, and its reduced form, CoQ10H2. B. 
Rotenone inhibits electron transport at C(1), blocking transfer of electron to CoQ10 and 
thus to C(III), preventing generation of the proton gradient across the mitochondrial 
inner membrane, depolarizing the mitochondrial membrane potential (ΔΨm) and 
depressing ATP production. Compensatory activation of glycolysis increases lung 
lactate generation as a reflection of increased cytosolic NADH levels. C. When the 
exogenous amphipathic quinone (Q1) is present, it freely enters the lung tissue, where 
it is reduced via cytosolic NQO1 at the expense of the endogenous electron donor, 
NAD(P)H. The reduced hydroquinone form, Q1H2, enters the mitochondria and 
transfers the reducing equivalents gained in the cytosol to C(III), thereby restoring 
mitochondrial electron transport, proton pumping, ΔΨm and ATP generation. The 
reoxidized quinone (Q1) returns to the cytosol to repeat the cycle. Thus, the Q1-Q1H2 
redox pair acts to shuttle electrons from cytosolic NAD(P)H to C(III). 
CoQ1 was selected as the candidate quinone because we have 
previously studied its redox metabolism on passage through the 
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isolated perfused rat lung. CoQ1 freely diffuses from the perfusate into 
the lung tissue and is reduced to its hydroquinone form (CoQ1H2) via 
cytosolic NAD(P)H quinone oxidoreductase 1 (NQO1) [2]. The CoQ1H2 
produced crosses the mitochondrial membrane to act as an electron 
donor at mitochondrial electron transport complex III [2]. Thus, since 
the CoQ1-CoQ1H2 redox pair undergoes all the steps that theoretically 
would be needed to effect a complex I bypass in the isolated perfused 
lung, we hypothesized that CoQ1 administration would restore 
mitochondrial bioenergetics, exemplified as ATP generation, and 
protect the pulmonary endothelial barrier from complex I blockade 
induced hyperpermeability, should it occur. 
Materials and Methods 
Materials 
2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-
benzoquinone (coenzyme Q1, hereafter referred to as CoQ1) was 
purchased from Sigma. Bovine serum albumin (BSA) was purchased 
from Equitech-Bio Inc. Lactate and pyruvate assay kits were obtained 
from BioVision. All other chemicals, unless otherwise noted, were 
purchased from Sigma. 
Animals 
Male Sprague-Dawley rats (Charles River) were housed in room 
air with free access to food and water. The animal protocol was 
approved by the Institutional Animal Care and Use Committee (IACUC) 
of the Zablocki VAMC, Milwaukee, WI USA 53295. 
Isolated perfused lung 
Rats were anesthetized with pentobarbital sodium (40 mg/kg 
body wt. i.p.), the chest opened and heparin (0.7 IU/g body wt.) 
injected into the right ventricle. The lung and heart were removed 
from the chest en bloc and suspended from a ventilation-perfusion 
system without (n = 36) or with (n = 39) a calibrated force transducer 
in place. The lung was ventilated (40 breaths per minute) with a gas 
mixture containing 15% O2, 6% CO2, balance N2, with end-inspiratory 
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and end-expiratory pressures of 8 and 3 cm H2O, respectively. The 
lung was perfused (0.03 ml·min−1·gram−1 body weight) with a 
physiologic salt solution containing (in mM) 4.7 KCl, 2.51 CaCl2, 1.19 
MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO3, 5.5 glucose and 5% bovine 
serum albumin. The perfusate was maintained at 37°C and 
equilibrated with the same gas mixture used for ventilation, resulting 
in perfusate PO2, PCO2 and pH of ~105 Torr, 40 Torr and 7.4, 
respectively. An initial volume of perfusate (~40 ml) was flushed 
through the lung and discarded, after which time the lung was 
perfused from a recirculating reservoir containing fresh perfusate. 
During the initial 10 minutes of recirculation, the venous effluent 
pressure (Pv) was held at atmospheric pressure, allowing time for the 
pulmonary arterial pressure (Pa) to stabilize. Pa was referenced to 
atmospheric pressure at the level of the left atrium and monitored 
continuously during the course of the experiment. 
Following the 10 minute stabilization period, the perfused lungs 
entered one of two protocols, each described below. In the first 
protocol, lungs were flash frozen in liquid N2 for measurements of 
adenine nucleotides and oxidized (GSSG) and reduced (GSH) forms of 
glutathione. In the second protocol, pulmonary endothelial 
permeability was measured as the pulmonary endothelial filtration 
coefficient (Kf) [22]. In both protocols, samples of pulmonary venous 
effluent were collected and flash frozen in liquid N2 for measurements 
of perfusate lactate and pyruvate levels. All biochemical 
measurements were normalized to one gram of dry lung weight. 
Protocol 1: Lung Adenine Nucleotides, GSH and GSSG  
Following a 10 minute stabilization period of lung perfusion, the 
perfusion pump was briefly halted, the reservoir emptied and refilled 
with 35 ml fresh perfusate containing vehicle only, rotenone (20 M), 
rotenone + CoQ1 (50 μM), CoQ1 alone (50 μM), rotenone + CoQ1 + 
dicumarol (400 μM), or rotenone + CoQ1 + antimycin A (3.6 μM). We 
have previously shown that at these concentrations, rotenone and 
CoQ1 do not cause any detectable changes in lung hemodynamics or 
wet:dry weight ratios [2]. 
The pump was restarted and the first 10 ml of pulmonary 
venous effluent was discarded, after which the remaining perfusate 
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was recirculated through the pulmonary circulation for 15 minutes. 
After 15 minutes, a 1 ml perfusate sample was collected from the 
reservoir, flash frozen in liquid N2 and stored at −80°C for 
measurement of lactate and pyruvate. Perfusion was halted, the lung 
quickly cut away from the heart and connective tissue, weighed, flash 
frozen in liquid N2, lyophilized to a constant weight, reweighed and 
ground to a powder, which was dispensed into weighed samples of 
~25 mg for storage at −80°C. 
Adenine nucleotides were extracted from the lung powder 
samples by addition of 5% perchloric acid (750 μl) followed by 
centrifugation (10,000 × g, 5 min, 4°C) and neutralization of 500 μl of 
supernatant with 400 μl K2HPO4 (1M). Sixty (60) μl of the extract was 
mixed with 75 μl of potassium phosphate buffer (64.35 mM, pH 6.0) 
containing 2.57 mM tetrabutylammonium hydrogen sulfate (2.57 mM), 
the latter solution being the initial HPLC mobile phase. The solution 
was filtered through a Nalgene 0.2 μm pore size cellulose acetate 
syringe filter (Nalge Nunc International, Rochester, NY) prior to 
injection onto the HPLC system. The HPLC system and mobile phase 
were as previously described, with the difference being substitution of 
a Phenomenex Kenetix C18 column (2.6 μm particle size, 100 × 4.6 
mm) [33]. 
The adenine nucleotides were quantified against standards 
prepared for each experiment, and the values normalized to 1 gm dry 
lung powder, based on the weights of the individual lung powder 
fractions used for each individual extraction. The adenylate energy 
charge was then calculated as = (ATP + ½ ADP)/(ATP + ADP + AMP) 
[34, 35]. 
GSSG and GSH glutathione were extracted from the lung 
powder samples by addition of 2.5% ice cold sulfosalicylic acid 
containing 0.2% Triton X-100 (final concentration of lung powder, 13.5 
mg per ml extraction solution). The extraction mixture was centrifuged 
(10,000 × g for 5 min at 4°C) and the resulting supernatant diluted 
1:10 in 0.1 M sodium phosphate buffer (pH = 7.4) for determination of 
GSSG and GSH, using the 5,5′-dithio-bis-(2-nitrobenzoic acid)-GSSG 
reductase recycling assay [36-38]. 
Protocol 2: Pulmonary Endothelial Permeability (Kf)  
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The perfused lungs were suspended from a calibrated force 
displacement transducer (Model FT03, Grass Instruments) and lung 
weight was monitored continuously. Following a 10 min stabilization 
period with Pv set at atmospheric pressure, the perfusate pump was 
stopped. The reservoir was emptied, then refilled with 35 ml fresh 
perfusate containing vehicle only (control), the complex I inhibitor 
rotenone (20 μM) or rotenone (20 μM) + CoQ1 (50 μM), or CoQ1 alone 
(50 μM). Alternatively, the complex I inhibitor piericidin A (1 μM) was 
used in place of rotenone. With the reservoir stirring continuously, the 
pump was restarted, the first 10 ml of venous effluent was discarded, 
and the remaining perfusate was recirculated through the pulmonary 
circulation. After 10 min of recirculation Pv was raised to ~5 cm H2O 
(zone III conditions) and the lung was perfused for 20 min. At the end 
of the 20 min, 1 ml of perfusate was collected from the stirred 
reservoir, flash frozen in liquid N2 and stored at −80°C for 
measurements of lactate and pyruvate. Then, Pv was raised to ~13.5 
cm H2O and perfusion continued for an additional 10 min. These step 
changes in pressure were more than adequate to allow appropriate 
measure of Kf [22]. 
Kf was determined by dividing the rate of weight gain measured 
10 minutes after increasing Pv from 5 to 13.5 cm H2O by the change in 
pulmonary capillary pressure (Pc), the latter estimated as (Pa + Pv)/2. 
The rate of weight gain at Pv ≅ 13.5 cm H2O was corrected for any 
nonisogravimetric weight gain during the Pv ≅ 5 cm H2O period. Kf was 
normalized per 1 gram dry lung weight. 
Statistics 
A one- way ANOVA with multiple comparisons was carried out 
by the Waller-Duncan k-ratio t test method using SAS 9.2. [39]. The 
Waller-Duncan test is an adaptive test which uses a very conservative 
(as large as the Bonferroni) critical value if the overall groups p value 
is near 0.05 and a much smaller critical value (nearly Fisher’s critical 
value) when the overall test is quite significant, thus showing that 
there are many differences to detect. It provides more clarity and 
power to detect differences between groups than methods that are 
static in cutoff. In addition, since many of the variables have different 
standard deviations in the groups, a log transformation of each data 
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point was used to stabilize the variance – a key assumption for an 
ANOVA. The results were then transformed back to the original scale. 
Results 
The effects of rotenone alone (20 M) or rotenone + CoQ1 (50 
μM) on lung ATP, ADP and AMP content are shown in Table 1. 
Rotenone depressed lung ATP content and elevated ADP and AMP. 
When CoQ1 was also present (rotenone + CoQ1), ATP, ADP and AMP 
levels were indistinguishable from those in the untreated control lungs, 
demonstrating that CoQ1 prevented the rotenone-induced lung ATP 
depletion and adenine nucleotide imbalance. In contrast, the effects of 
rotenone on lung ATP, ADP and AMP could not be overcome by CoQ1 
when inhibitors of NQO1 (dicumarol) or complex III (antimycin A) 
were also present (Table 1). The requirement for active NQO1 and 
complex III for maintenance of lung ATP is consistent with a CoQ1 
mechanism involving complex I bypass, wherein CoQ1 is reduced to 
CoQ1H2 by NQO1 and the CoQ1H2 produced is reoxidized at complex 
III, as depicted in Scheme 1C. 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Free Radical Biology and Medicine, Vol. 65 (December 2013): pg. 1455-1463. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
11 
 
 
 
Table 1 Rat lung tissue adenine nucleotide content (μmol·gram−1 dry lung) 
after 15 min of perfusion with the experimental treatments in Protocol 1 
studies 
The values are means ± SE. Statistical analysis was carried out using ANOVA, with 
multiple comparisons made using the Waller-Duncan k-ratio t-test. Means with the 
same letter designations are in the same group and not significantly different 
(p>0.05). Means with two letters are not different from either group. Means with 
different letter designations are in different groups and are significantly different from 
each other (p<0.05). 
Figures 1A - C show the lung ADP:ATP ratios, AMP:ATP ratios 
and energy charges calculated from the Table 1 data, where energy 
charge is defined as (ATP + ½ ADP)/(AMP + ADP + ATP). As compared 
to control, rotenone increased the ADP:ATP and AMP:ATP ratios and 
depressed the energy charge. When CoQ1 was present along with 
rotenone, the ADP:ATP and AMP:ATP ratios and the energy charge 
were not detectably different from controls. When the NQO1 or 
complex III inhibitors, dicumarol or antimycin A, respectively, were 
included with CoQ1 + rotenone, they blocked the ability of CoQ1 to 
prevent the rotenone-induced disruption of adenine nucleotide 
balance, as exemplified in Figures 1A - C. 
Treatment  n  ATP  ADP  AMP  ATP + ADP 
+ AMP 
Vehicle Control 7 5.66 ± 0.46 b 1.17 ± 0.14 b,c 0.31 ± 0.06 c 7.15 ± 0.33 b 
Rotenone 8 2.34 ± 0.15 c 1.83 ± 0.09 a 1.73 ± 0.29 b 5.90 ± 0.37 c 
Rotenone + CoQ1 7 5.38 ± 0.29 b 1.22 ± 0.07 b 0.30 ± 0.04 c 6.90 ± 0.35 b,c 
CoQ1 4 7.72 ± 0.36 a 0.93 ± 0.05 c 0.14 ± 0.04 d 8.79 ± 0.34 a 
Rotenone + CoQ1 + 
Dicumarol 
5 1.23 ± 0.09 e 1.58 ± 0.04 a 3.12 ± 0.22 a 5.93 ± 0.35 c 
Rotenone + CoQ1 + 
Antimycin 
A 
5 1.68 ± 0.05 d 1.58 ± 0.04 a 2.84 ± 0.30 a 6.10 ± 0.23 c 
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Figure 1 Rat lung tissue ADP/ATP ratios (A), AMP/ATP ratios (B) and 
energy charges (C) after 15 min of perfusion with experimental treatments 
The ratios and energy charges (mean ± SE) were calculated from the individual lung 
data used to calculate the mean values in Table 1. Energy charge was calculated as 
(ATP + ½ ADP)/(ATP + ADP + AMP). Statistics were carried out as described in Table 
1, wherein means with the same letter designation are not significantly different from 
each other (p<0.05); means with different letters are significantly different. 
Figure 2 shows the fractional ATP, ADP or AMP concentrations vs 
the energy charges calculated for each of the 36 individual lungs used 
to obtain the mean values in Table 1. This representation emphasizes 
the wide range in lung energy charges produced by the experimental 
treatments. The solid lines represent the theoretically predicted 
proportions of ATP:ADP:AMP at any given energy charge under the 
assumption that the adenylate kinase reaction is a key factor 
regulating the equilibrium levels [34, 35] (See Appendix). 
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Figure 2 Lung tissue fractional concentrations of ATP, ADP and AMP vs 
energy charge for the experimental treatments in Protocol 1 studies 
The symbols are the fractional adenine nucleotide values calculated from individual 
lung adenine nucleotide measurements that make up the mean values in Table 1 (n = 
36). Energy charge was calculated as described in the Figure 1 legend. The solid lines 
show the theoretical proportions of ATP, ADP and AMP present at the indicated energy 
charge if the adenylate kinase equilibrium [ATP][AMP]/[ADP]2 = 1.2 was controlling 
the relative amounts of the adenine nucleotides [35]. 
Table 2 shows the effects of the treatment conditions on lung 
lactate and pyruvate production, and the total lactate + pyruvate 
levels. As compared to control, rotenone increased lung lactate 
generation with no detectable effect on pyruvate, suggesting activation 
of glycolysis as a compensatory response to complex I blockade [40]. 
Then, as compared to rotenone alone, CoQ1 + rotenone decreased 
lactate levels and increased pyruvate levels (Table 2), implying that 
CoQ1 tends to dampen the impact of rotenone to activate glycolysis. 
The increase in pyruvate is apparent for every Table 2 treatment 
containing CoQ1. The effect of CoQ1 to mitigate the rotenone-induced 
increase in glycolytic activity, as reflected by lactate levels, was 
effectively blocked by dicumarol and antimycin A (Table 2). Figure 3 
shows the negative correlation between lactate levels (i.e., glycolytic 
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activity) and energy charge across the treatment groups, suggesting 
that activation of glycolysis could not fully compensate for the energy 
deficit induced by complex I blockade. 
 
Figure 3 Lung perfusate lactate vs lung tissue energy charge in Protocol 1 
studies 
Each symbol represents the lactate level for an individual lung (from Tables 1 and 
and2),2), plotted vs the energy charge calculated for the same lung. Pearson Product 
Moment Correlation r = 0.837, p<0.01. 
 
Treatment  n  Lactate  Pyruvate  Lactate + 
Pyruvate 
Vehicle Control 4 12.36 ± 1.64 c 0.88 ± 0.11 d 13.24 ± 1.66 c 
Rotenone 4 38.62 ± 3.14 a 0.87 ± 0.14 d 39.49 ± 3.12 a 
Rotenone + CoQ1 3 24.64 ± 1.96 b 2.58 ± 0.20 a 27.23 ± 1.92 b 
CoQ1 4 14.77 ± 2.02 c 2.12 ± 0.18 a,b 16.90 ± 2.08 c 
Rotenone + CoQ1 + 
Dicumarol 
4 34.31 ± 0.81 a 1.70 ± 0.26 b,c 36.01 ± 0.97 a 
Rotenone + CoQ1 + 
Antimycin A 
4 34.63 ± 2.22 a 1.42 ± 0.06 c 36.05 ± 2.19 a 
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Table 2 Lung lactate and pyruvate production over the 15 min treatment 
periods (μmol ·15 min−1·gram−1 dry lung) in Protocol 1 studies 
Measurements were made in pulmonary venous effluent samples of a subset of lungs 
in Table 1. The values are means ± SE. Statistical analysis was carried out as 
described in Table 1. Means with the same letter designation are in the same group 
and not significantly different (p>0.05); means with different letter designations are in 
different groups and significantly different from each other (p<0.05). 
Figure 4 shows the effect of the treatment conditions on lung 
tissue lactate and pyruvate levels expressed as the lactate/pyruvate 
ratio, as an index of cytosolic NADH/NAD+ status. Rotenone 
substantially increased the ratio as compared to control, and when 
CoQ1 was added with rotenone, the ratio was normalized. However, 
with CoQ1 alone, the ratio was actually lower than control, a reflection 
of the general CoQ1 impact on pyruvate levels seen in Table 2. This 
CoQ1 effect also comes into play when dicumarol or antimycin are 
added, wherein we might expect either to more convincingly block the 
mitigating effect of CoQ1 on the rotenone-induced increase in 
lactate/pyruvate ratio. Table 3 shows that despite the large effect 
rotenone had on the lactate/pyruvate ratio, it had no detectable 
impact on whole lung glutathione redox status (GSH/GSSG). 
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Figure 4 Lung perfusate lactate/pyruvate ratios produced by the 
treatments in Protocol 1 studies 
The lactate/pyruvate ratios (mean ± SE) were calculated from the individual lung 
lactate and pyruvate data used to calculate the mean values in Table 2. Statistical 
analysis was carried out as described in Table 1. Means with the same letter 
designation are not significantly different (p>0.05); means with different letter 
designations are significantly different from each other (p<0.05). 
 
 
 
 
 
Table 3 Lung tissue reduced (GSH) and oxidized (GSSG) glutathione after 
15 min perfusion with rotenone (μmol·gram−1 dry lung) in Protocol 1 studies 
Values are means ± SE. There were no statistically significant differences (t-test, 
p>0.05). 
Table 4 shows that there were no statistically significant effects 
of Protocol 1 study conditions or treatments on lung wet-dry weight 
ratios or pulmonary arterial perfusion pressures, and thus no 
detectable overt, non-specific lung injury. 
Treatment  n  Body  
Weight (g)  
Lung Wet to Dry  
Weight Ratio  
Pulmonary  
Arterial Pressure  
(cm H2O)  
Vehicle Control 7 362.9 ± 27.6 5.87 ± 0.24 7.3 ± 0.9 
Rotenone 8 362.4 ± 31.8 5.83 ± 0.13 6.8 ± 0.5 
Rotenone + CoQ1 7 387.7 ± 41.6 5.67 ± 0.20 6.9 ± 0.7 
CoQ1 4 322.0 ± 7.1 5.29 ± 0.07 6.6 ± 0.4 
Rotenone + CoQ1 + Dicumarol 5 326.4 ± 6.4 5.88 ± 0.14 6.4 ± 0.3 
Rotenone + CoQ1 + Antimycin 
A 
5 316.6 ± 3.4 5.55 ± 0.12 6.3 ± 0.7 
 
Table 4 Body weights, lung wet:dry weight ratios and pulmonary arterial 
(perfusion) pressures for Protocol 1 studies 
Data are means ± SE. There were no statistically significant differences between 
parameter values in the different study groups (p > 0.05). 
The isolated perfused rat lung was treated with the complex I inhibitor rotenone. 
Rotenone depressed lung ATP and energy charge with no detectable impact on 
GSH:GSSG. Rotenone increased the pulmonary endothelial filtration coefficient (Kf). 
Coenzyme Q1 largely prevented the effects of rotenone in the lung. 
The CoQ1 mechanism was via complex I bypass and restoration of lung ATP 
generation. 
Treatment  n  GSH  GSSG  GSH + GS GSH/GSSG  
Vehicle Control 7 10.71 ± 0.77 0.36 ± 0.05 11.44 ± 0.84 32.61 ± 4.40 
Rotenone 8 9.73 ± 0.69 0.34 ± 0.03 10.35 ± 0.70 30.76 ± 3.94 
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Figure 5 shows the impact of rotenone on pulmonary endothelial 
permeability, in the absence or presence of CoQ1, measured as Kf in 
Protocol 2 studies. We note that conditions were met for accurate 
estimation of Kf [22]: step changes in pressure were more than 
adequate and the treatments had no detectable effects on 
hemodynamic parameters (Pa, Pv, pulmonary vascular resistance or 
pulmonary capillary pressure, data not shown). Kf was 3.6 fold higher 
in rotenone-treated than control lungs (p < 0.05). CoQ1 prevented the 
rotenone-induced increase in Kf, without having a detectable impact on 
its own (Figure 5). Further, as shown in Figure 6, the Protocol 2 study 
conditions used to determine Kf did not in and of themselves influence 
the impact of the treatment conditions on lung cytosolic redox status, 
as reflected in the lactate:pyruvate ratios, since these were reasonably 
similar to those obtained in the Protocol 1 studies (Figure 4). 
 
Figure 5 Effect of rotenone and CoQ1 on the filtration coefficient (Kf) in rat 
lung in Protocol 2 studies 
The bars represent the means ± SE for Kf measured in vehicle control (n = 13), 
rotenone (n = 6), rotenone + CoQ1 (n = 6), or CoQ1 (n = 7) treated lungs. Means with 
the same letter designation are not significantly different (p>0.05); means with 
different letter designations are significantly different from each other (p<0.05). 
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Figure 6 Lung perfusate lactate/pyruvate ratios in lungs undergoing Kf 
procedure in Protocol 2 studies 
The ratios (mean ± SE) obtained from Figure 5 studies, including vehicle control (n = 
13), rotenone (n = 6), rotenone + CoQ1 (n = 6) and CoQ1 only (n = 7) treated lungs. 
Statistical analysis was carried out as described in Table 1. Means with the same letter 
designation are not significantly different (p>0.05); means with different letter 
designations are significantly different from each other (p<0.05). 
Finally, Figure 7 shows that an alternative complex I inhibitor, 
piericidin A, produced qualitatively similar effects to rotenone on the Kf 
and lactate:pyruvate ratios in Protocol 2 studies. 
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Figure 7 Effect of the complex I inhibitor piericidin A on Kf and lung 
perfusate lactate/pyruvate ratios in Protocol 2 studies 
The bars represent the means ± SE for Kf measured in vehicle controls (n = 13) or 
piericidin A (n = 7) treated lungs. * Significantly different from control (p<0.05; t-
test). 
Discussion 
The study demonstrates that rotenone-induced blockade of 
mitochondrial electron transport complex I in the isolated perfused rat 
lung resulted in ATP depletion and depression of the adenylate energy 
charge. Rotenone also increased perfusate lactate levels, the 
lactate:pyruvate ratio, and pulmonary vascular endothelial 
permeability, measured as Kf. A second complex I inhibitor, piericidin 
A, qualitatively reproduced the impact of rotenone on Kf and the 
lactate:pyruvate ratio. 
The quinone CoQ1 largely prevented the impact of rotenone on 
lung tissue ATP levels, energy charge and lactate production. The 
ability of CoQ1 to prevent the effects of rotenone on these biochemical 
parameters depended on both NQO1 and complex III activities. In 
separate studies, CoQ1 also blocked the rotenone-induced increase in 
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Kf. Under the assumption that this CoQ1 effect on Kf involves 
restoration of mitochondrial bioenergetics, reflected as ATP generation, 
and thus would also depend on NQO1 and complex III activities, the 
study implicates a CoQ1 mechanism involving a cytosolic-mitochondrial 
electron shuttle that bypasses complex I to restore mitochondrial 
electron transport by transfer of electrons to complex III. This 
sequence of quinone:hydroquinone redox reactions with restoration of 
mitochondrial respiration in pharmacological or genetic complex I 
dysfunction has been reported in the isolated perfused rat lung using 
duroquinone, and by others in various cell and isolated mitochondrial 
preparations using a range of quinones [26-29]. However, to our 
knowledge, the present findings provide the first evidence showing 
bioenergetic and functional protection afforded by a quinone in a 
complex I activity-deficient intact organ preparation and implicating 
complex I bypass as the mechanism,. 
In our study, the read-out for blockade of mitochondrial electron 
transport was ATP production and the adenylate energy charge. The 
energy charge vs fractional ATP, ADP and AMP relationships shown in 
Figure 2 suggest that the lung is a highly energized and metabolically 
active organ, able to maintain a predictable ATP:ADP:AMP equilibrium 
across a range of bioenergetic manipulations, consistent with previous 
studies [1, 9, 41]. The solid lines in Figure 2 represent the 
theoretically predicted proportions of ATP:ADP:AMP at any given 
energy charge. This prediction is based on the assumption that the 
adenylate kinase reaction is a key factor regulating the equilibrium 
levels [34, 35] (see Appendix). Insofar as adenylate kinase has been 
implicated as a key reaction regulating energy balance and ATP 
availability under conditions of increased stress, represented here by 
rotenone treatment, the close adherence of the data to the prediction 
is consistent with the concept of this enzyme as such a regulatory 
factor, and suggest that the treatments did not exert non-specific 
effects on adenylate kinase and/or other components involved in this 
process [42]. 
The impact of rotenone on lung perfusate lactate and pyruvate 
levels implies that complex I blockade evoked a compensatory 
increase in glycolytic activity, as in other lung studies using rotenone 
or other mitochondrial inhibitors [1, 23, 40, 43]. Accordingly, the 
rotenone effect on the lactate/pyruvate ratio is consistent with 
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inhibition of mitochondrial electron transport [23]. Of course, like the 
adenine nucleotide measurements, perfusate lactate and pyruvate 
levels represent the whole lung. Whereas the relative contribution 
arising from any given lung cell type or tissue compartment is 
unknown, and even the relative contribution of mitochondrial vs 
glycolytic energy production in the in situ pulmonary endothelium is 
debated, we would expect that pulmonary endothelial cells contribute 
substantially to the net effect based on their contribution to total lung 
cell volume. Nevertheless, glycolysis could not fully compensate for 
the adenylate energy imbalance caused by complex I blockade, nor 
could it overcome the functional consequence of complex I blockade, 
i.e., pulmonary endothelial hyperpermeability. This observation is 
consistent with a previous study showing that glycolysis was not 
required to maintain pulmonary endothelial-epithelial barrier function 
in the perfused rabbit lung [40]. In contrast to the intact lung, 
pulmonary endothelial cells in culture required simultaneous inhibition 
of glycolytic and mitochondrial ATP generation to evoke a permeability 
response [44]. The implication is that the relative contribution of 
mitochondrial bioenergetic function to pulmonary endothelial barrier 
integrity is more dominant in the intact lung than in cell culture 
conditions. 
Whereas CoQ1 prevented the rotenone-induced depression in 
ATP, and tended to dampen the impact of rotenone on glycolysis (as 
reflected in lactate levels), the elevated pyruvate generation whenever 
CoQ1 was present suggests that it may have done so at the expense of 
cytosolic NADH, as a source of reducing equivalents for reduction of 
both CoQ1 and pyruvate, the latter via the lactate dehydrogenase 
reaction. Then the CoQ1-induced effect on pyruvate could be explained 
as competition for NADH. However, although we did not carry out a 
flux analysis, the observation that the CoQ1-induced increases in 
pyruvate account for only ~ 2 – 4% of the total lactate + pyruvate 
suggests an additional or supplementary electron donor pathway for 
CoQ1 reduction. Our previous observations implicate pentose 
phosphate pathway generated NADPH, which we showed to be the 
predominant source of reducing equivalents for NQO1-catalyzed 
duroquinone reduction in pulmonary endothelial cells in culture [33]. 
We also demonstrated that the majority of CoQ1 reduction on passage 
through the rat pulmonary circulation in the presence of rotenone is 
via NQO1 [2]. Under the assumption that NADPH would also be a 
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dominant electron donor for NQO1-catalyzed CoQ1 reduction in the rat 
lung, quinone activation of the pentose phosphate pathway would 
generate the NADPH to reduce CoQ1 (via the oxidative branch) and 
explain a CoQ1 effect to increase glycolytic intermediates (via the non-
oxidative branch). Then the net result of CoQ1 would be enhanced ATP 
generation via both mitochondrial and glycolytic pathways. 
Inhibition of mitochondrial electron transport with rotenone or 
piericidin A has been implicated in reactive oxygen species (ROS) 
generation in some cell types and sub-cellular preparations [45-48]. 
However, in the lung and pulmonary endothelial cells, several reports 
indicate that acute rotenone treatment actually suppresses ROS 
generation induced by various stimuli, including elevated pulmonary 
capillary pressure or hyperoxia [49-53]. We did not measure ROS 
generation per se, but the rotenone treatment in the present study did 
not deplete GSH or alter the GSH:GSSG ratio in whole lung tissue, 
suggesting that if excessive ROS production occurred, it did not cause 
global, overt oxidative stress. However, we acknowledge that the 
GSH:GSSG ratio in total lung tissue may not reveal mild or 
compartmentalized ROS generation that could initiate a focal Ca2+-
dependent hyperpermeability response [54]. In that case, CoQ1 
mitigation of the rotenone-induced permeability response might be 
attributed to the antioxidant activity of CoQ1H2. However, we do not 
favor this interpretation, as it does not account for the observation 
that complex III inhibition blocks the mitigating effect of CoQ1 on 
adenine nucleotide balance under conditions in which CoQ1H2 would 
continue to be generated via NQO1. 
Another potential mechanism by which rotenone could impact 
pulmonary endothelial permeability is via direct disruption of 
microtubule assembly, wherein microtubules are an essential 
cytoskeletal element influencing permeability of cultured endothelial 
cell monolayers [55-58]. Whether rotenone is acting as a microtubule 
disrupter in the present study was not evaluated. However, insofar as 
CoQ1 protected against the impact of rotenone on Kf, and if anything, 
certain other quinones cause microtubule disruption, a CoQ1 
mechanism involving direct microtubule stabilization seems unlikely 
[59]. 
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We have interpreted the data from the perspective that Kf 
reflects primarily endothelial permeability in the isolated lung. This 
interpretation must take into account the recognition of lung 
endothelial heterogeneity, that is, the notion that endothelium in lung 
extra-alveolar vessels and the alveolar septal compartment display 
distinct metabolic and permeability-responsive phenotypes [60]. For 
example, lung microvascular endothelial cells, at least in cell culture, 
are more glycolytic than those derived from the pulmonary artery 
[61]. The more glycolytic phenotype may confer a relative insensitivity 
to mitochondrial blockade, relegating the increased permeability 
response to the larger extra-alveolar vessels. Nevertheless, we found 
that glycolysis, no matter how robust, failed to fully compensate for 
the rotenone effects on energy charge or pulmonary endothelial 
permeability. 
A straightforward explanation of the rotenone-induced increase 
in Kf is that disruption of mitochondrial bioenergetic function, reflected 
as ATP depletion, impairs the pulmonary endothelial permeability 
response, an effect mitigated by CoQ1. Several potential mechanisms 
should be considered here. First, ATP could be required as the energy 
source for repletion of intracellular Ca2+ stores that drive store 
operated channel-mediated pulmonary endothelial permeability 
responses [62]. If true, ATP depletion would preferentially impact 
permeability in extra-alveolar vessels and lead to perivascular cuffing 
rather than alveolar flooding. Yet we observed that lungs treated with 
rotenone or piericidin A tended to develop frank alveolar flooding by 
the end of the perfusion period. Second, viewing ATP depletion in a 
broader sense, as a biomarker of mitochondrial dysfunction, other 
possibilities arise, including impaired mitochondrial Ca2+ handling [62-
64]. While a role for mitochondrial Ca2+ has not been evaluated in the 
context of pulmonary endothelial barrier function, it has been 
implicated in transducing pressure-induced pro-inflammatory 
responses in lung venular capillaries [53]. If mitochondrial Ca2+ 
signaling is a mechanism of pulmonary endothelial barrier dysfunction, 
we predict that the effect would not be restricted to a specific lung 
vascular compartment. Finally, Kf may also be influenced by depressed 
activity of the alveolar epithelial Na+/K+-ATPase, wherein tight junction 
structure and permeability are highly ATP-dependent in alveolar and 
other epithelial cells [65-67]. However, while rotenone exposure 
mimics the hyperoxia-induced decrease in complex I activity observed 
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in rats breathing 85% O2 for 48 hours, exposure to the same sub-
lethal oxygen tension, albeit for longer time courses, is associated with 
increased trans-epithelial sodium transport, and thus increased 
alveolar fluid clearance [68]. Further observations that alveolar 
epithelial Na+2 transport can be supported by glycolysis in the 
presence of mitochondrial inhibitors, including rotenone, has actually 
led others to conjecture that the pulmonary endothelium is the site of 
barrier failure in mitochondrial insufficiency [43]. In light of these 
studies, the implication is that the pulmonary endothelium is also a 
predominant site of the hyperoxia-induced increase in Kf observed in 
the rabbit lung [25]. Nonetheless, our conclusion that complex I 
bypass affords significant protection against rotenone-induced barrier 
dysfunction in lung remains valid regardless of whether the 
endothelium, epithelium or both provide the main target. 
Conclusion 
Mitochondrial bioenergetic dysfunction, reflected as ATP 
depletion, and/or decreased activity of electron transport complexes or 
other mitochondrial components have been reported in various forms 
of experimental and clinical lung disease, including hyperoxia, 
phosgene- or paraquat-induced lung injury, ischemia reperfusion 
injury, in lung preservation for transplantation and in chronic 
obstructive pulmonary disease [9, 16-21]. One aspect of such 
dysfunction is a deficiency in movement of reducing equivalents 
through the mitochondrial electron transport chain and ATP depletion. 
Amphipathic CoQ10 homologs and analogs (e.g., CoQ1) restore 
mitochondrial function and ATP generation by shuttling reducing 
equivalents from the cytosol to the mitochondria [28-30, 32]. This 
mechanism provides one basis for use of quinones in treating patients 
with neurological and other disorders associated with genetic 
mitochondrial deficiencies [31]. The present study demonstrates that 
CoQ1 prevents energy charge depletion and pulmonary endothelial 
hyperpermeability evoked by complex I blockade in the isolated 
perfused rat lung, and provides evidence that the impact on energy 
charge is via a cytosolic-mitochondrial electron shuttle. The implication 
is that certain quinones may also be beneficial in protection of the lung 
from pulmonary edema associated with acute lung injury, when the 
injury involves mitochondrial dysfunction. 
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Supplementary Material 
Appendix: 
Adenylate kinase catalyzes the following reaction: 
 
Using mass action: 
 
Then using algebraic manipulation of equations (1-2), one could show 
that: 
 
Thus, for a given EC and K values, equation (4) can used to determine 
[ADP]. Knowing [ADP], then [ATP] and [AMP] are determined from 
equation (2) and equation (3), respectively. 
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